Article Detail - JE Part B
MLN Connects Special Edition - December 9, 2020
In Case You Missed It: CMS Announces Guidance for Medicare Coverage of COVID-19 Antibody Treatment
On December 9, CMS posted updates to FAQs and an infographic about coverage and payment for monoclonal antibodies to treat COVID-19. The FAQs include general payment and billing guidance for these products, including questions on different setting types. The infographic has key facts about expected Medicare payment to providers and information about how Medicare beneficiaries can receive these innovative COVID-19 treatments with no cost-sharing during the public health emergency (PHE). CMS’ November 10, 2020 announcement about coverage of monoclonal antibody therapies allows a broad range of providers and suppliers, including freestanding and hospital-based infusion centers, home health agencies, nursing homes, and entities with whom nursing homes contract, to administer this treatment in accordance with the Food & Drug Administration’s Emergency Use Authorization (EUA), and bill Medicare to administer these infusions. Currently, two monoclonal antibody therapies have received EUA’s for treatment of COVID-19.
For More Information:
- Therapeutics Coverage Infographic
- Section BB of the FAQs: billing and payment for COVID-19 monoclonal antibody treatments
- Monoclonal toolkit and program guidance
